Institut de Myologie, Paris, France.
Department of Paediatrics, MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, United Kingdom.
Ann Clin Transl Neurol. 2021 Oct;8(10):1938-1950. doi: 10.1002/acn3.51417. Epub 2021 Aug 28.
To understand the natural disease upper limb progression over 3 years of ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) using functional assessments and quantitative magnetic resonance imaging (MRI) and to exploratively identify prognostic factors.
Forty boys with DMD (22 non-ambulatory and 18 ambulatory) with deletions in dystrophin that make them eligible for exon 53-skipping therapy were included. Clinical assessments, including Brooke score, motor function measure (MFM), hand grip and key pinch strength, and upper limb distal coordination and endurance (MoviPlate), were performed every 6 months and quantitative MRI of fat fraction (FF) and lean muscle cross sectional area (flexor and extensor muscles) were performed yearly.
In the whole population, there were strong nonlinear correlations between outcome measures. In non-ambulatory patients, annual changes over the course of 3 years were detected with high sensitivity standard response mean (|SRM| ≥0.8) for quantitative MRI-based FF, hand grip and key pinch, and MFM. Boys who presented with a FF<20% and a grip strength >27% were able to bring a glass to their mouth and retained this ability in the following 3 years. Ambulatory patients with grip strength >35% of predicted value and FF <10% retained ambulation 3 years later.
We demonstrate that continuous decline in upper limb strength, function, and MRI measured muscle structure can be reliably measured in ambulatory and non-ambulatory boys with DMD with high SRM and strong correlations between outcomes. Our results suggest that a combination of grip strength and FF can be used to predict important motor milestones.
通过功能评估和定量磁共振成像(MRI)了解 3 年内可步行和不可步行的杜氏肌营养不良症(DMD)患者上肢自然疾病进展,并探索预后因素。
纳入 40 名携带缺失导致抗肌萎缩蛋白的 DMD 男孩(22 名不可步行,18 名可步行),这些缺失使他们有资格接受外显子 53 跳跃治疗。每 6 个月进行临床评估,包括布鲁克评分、运动功能测量(MFM)、手握力和关键捏力,以及上肢远端协调性和耐力(MoviPlate),每年进行一次定量 MRI 脂肪分数(FF)和瘦肌肉横截面积(屈肌和伸肌)。
在整个人群中,结果测量之间存在很强的非线性相关性。在不可步行的患者中,3 年内每年的变化都可以通过基于定量 MRI 的 FF、手握力和关键捏力以及 MFM 进行高灵敏度标准反应均值(|SRM|≥0.8)检测到。FF<20%和握力>27%的男孩能够将杯子送到嘴边,并在接下来的 3 年内保持这种能力。握力>预测值的 35%和 FF<10%的可步行患者 3 年后仍能保持步行能力。
我们证明,在可步行和不可步行的 DMD 男孩中,上肢力量、功能和 MRI 测量的肌肉结构的持续下降可以通过高 SRM 和结果之间的强相关性来可靠地测量。我们的研究结果表明,握力和 FF 的组合可用于预测重要的运动里程碑。